The Medline Inc. (MDLN) SEC filings page on Stock Titan is designed to help investors and researchers review the company’s regulatory disclosures as it becomes and operates as a publicly traded company. Medline has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to an initial public offering of its common stock, and it has announced the effectiveness of that registration statement and the pricing and closing of an upsized initial public offering of Class A common stock on the Nasdaq Global Select Market.
As Medline continues to report as a public company, this page will surface filings such as registration statements, annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, when available. These documents are where Medline provides detailed information about its med-surg products and supply chain solutions, its two operating segments (Medline Brand and Supply Chain Solutions), its revenue sources, risk factors and other material business information.
Stock Titan enhances access to these filings with AI-powered summaries that explain the key points of lengthy documents in plain language. Instead of reading an entire registration statement or future 10-K, users can rely on AI-generated highlights that point to major business updates, capital structure changes, and disclosures related to Medline’s role as what it describes as the largest provider of med-surg products and supply chain solutions serving all points of care, based on total net sales of med-surg products.
The filings page also connects users to real-time updates from the SEC’s EDGAR system as new Medline filings are posted. Over time, this includes information on executive and insider transactions reported on Form 4, as well as proxy statements that describe governance and compensation matters. Together, these tools allow users to follow MDLN’s regulatory history and understand how Medline presents its business and risks in official SEC documents.
The Carlyle Group Inc. and affiliated reporting persons filed an amendment to a Schedule 13G disclosing beneficial ownership of Medline Inc. Class A common stock. The filing reports shared dispositive power of 187,083,713 shares (20.6%) held by certain Carlyle entities and additional shared positions of 145,591,597 shares (16.3%). The ownership disclosure cites 845,611,435 shares outstanding as of April 13, 2026 per the issuer's proxy statement and itemizes entity holdings such as 97,307,792, 50,719,101 and 48,283,805 shares among other affiliated funds and holdco vehicles. The amendment clarifies the fund/GP structure through which these positions are held and shared among reporting entities.
Medline Inc. ownership update: Abu Dhabi Investment Authority reports beneficial ownership of 41,355,340 shares of Class A Common Stock (including direct and shared holdings), representing 4.9% of the class. Platinum Falcon B 2018 RSC Limited reports 40,838,099 shares, representing 4.8%. The percent calculations are based on 845,611,435 shares outstanding as reported in Medline's March 6, 2026 prospectus.
Medline Inc. ownership disclosure: Hellman & Friedman-related reporting persons report beneficial ownership of 187,083,713 shares of Class A common stock as of March 31, 2026. The filing states the calculation base uses 845,611,435 shares outstanding from the issuer's March 6, 2026 prospectus plus 100,610,216 shares issuable upon exchange of Common Units.
The Amendment clarifies the allocation of holdings among affiliated entities (examples: HFCP X Parallel 74,496,172 shares; HFCP X Parallel-A 7,781,788 shares; Mend Partners II 4,176,227 shares) and describes exchange rights of Common Units into Class A shares.
Medline Inc. reported first-quarter 2026 net sales of $7.35 billion, up from $6.64 billion a year earlier, driven by both Medline Brand and Supply Chain Solutions. Net income was $239 million, with $129 million attributable to Medline Inc., or $0.16 per diluted share.
Adjusted EBITDA was about $0.8 billion, for a 10.6% margin, while operating cash flow was $412 million. The company ended the quarter with $2.24 billion in cash and $12.76 billion of debt, largely senior secured and unsecured notes.
Medline completed a December 2025 IPO that raised approximately $7.05 billion in net proceeds, most of which funded term-loan repayments and purchases of units from pre‑IPO owners. A March 2026 secondary offering saw selling stockholders dispose of 86.25 million Class A shares for about $3.5 billion; Medline received no proceeds but expects a higher share of future net income as noncontrolling interests declined by roughly 3%.
Medline Inc. reported first quarter 2026 results, showing strong sales growth but lower profitability. Net sales rose 10.7% to $7.35 billion, driven by new 2025 customer implementations and growth with existing customers, while Organic Sales increased 10.1%.
Net income fell 25.8% to $239 million, mainly from higher cost of goods sold, tariffs, added operating expenses to support growth, and an IPO-related employee bonus, partly offset by higher sales and lower interest expense. Adjusted EBITDA declined 10.6% to $776 million, and operating margin narrowed to 5.7%.
Diluted EPS was $0.16, with Adjusted Diluted EPS of $0.33. Net cash from operating activities was $412 million, and Free Cash Flow was $316 million, both lower than a year ago. Management raised full-year 2026 Organic Sales growth guidance to 8.5%–9.5% and maintained Adjusted EBITDA guidance of $3.5–$3.6 billion, reflecting confidence in demand despite cost pressures.
Medline Inc. reporting persons led by Blackstone-related entities disclosed beneficial ownership of 187,083,713 shares of Class A Common Stock as of March 31, 2026. The filing shows largest single reported holdings of 109,250,239 shares by BX Mozart ML-2 Holdco L.P. and an aggregate stake representing 20.6% of Class A shares based on 845,611,435 shares outstanding as of March 10, 2026.
The statement describes ownership through multiple Blackstone affiliates and related entities, explains conversion rights of Common Units into Class A shares one-for-one, and disclaims admission of beneficial ownership by certain reporting persons. Signatures and a joint filing agreement are included.
Medline Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 11, 2026, including electing 12 directors, advisory votes on executive pay and its frequency, and ratifying Ernst & Young LLP as independent auditor for 2026.
For 2025, Medline reported net sales of $28.4 Billion, an 11.5% year-over-year increase, and net income of $1.2 Billion, a 3.6% year-over-year decrease. Organic sales grew 10.5%, and Adjusted EBITDA was $3.5 Billion, up 3.2%. Net cash provided by operating activities was $1.7 Billion and free cash flow was $1.3 Billion.
Medline Inc. director Patrick J. Healy reported internal restructuring transactions involving Class A common stock, not open-market buying or selling. The filing shows a distribution in kind from investment funds affiliated with Hellman & Friedman to Healy and a related family trust.
After these transactions, Healy holds 1,208,159 Class A shares directly and 150,039 shares indirectly through a family trust, with an additional 39,189 shares held indirectly through a children's trust. The trusts are for the benefit of certain family members, and Healy disclaims beneficial ownership of those trust-held shares except to the extent of his pecuniary interest.
Medline Inc. major shareholder group led by The Carlyle Group Inc. reported a large secondary sale of Class A common stock. On 2026-03-10, entities affiliated with Carlyle sold 26,105,840 shares of Class A Common Stock at $41.00 per share in open-market or private transactions.
In a separate move the same day, Carlyle Mozart Coinvestment Holdings, L.P. made a pro-rata distribution of 2,113,483 Class A shares to its limited partner for no consideration, with those distributed shares subject to lock-up restrictions. After these transactions, Carlyle-affiliated entities reported indirect ownership of 125,454,241 Class A shares across multiple investment vehicles.